Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Fennec Pharmaceuticals Inc (FENC) Insider Trading Activity
Healthcare • Biotechnology • 29 employees
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Total Value
$129,259.05
Total Shares
51,832
Average Trade Value
$4,787.37
Most Active Insider
Raykov Rosty
Total Activity: $208,094
Largest Single Transaction
$67,250
by Raykov Rosty on Dec 20, 2024
30-Day Activity
7 Transactions
Volume: 29,633 shares
Value: $59,968
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
| Dec 20, 2024 | 25,000 | $67,250 | 91,432 (+27.3%) | Exercise/Conversion | ||
| Dec 5, 2024 | 796 | $4,808 | 66,432 (-1.2%) | Sale | ||
| Dec 3, 2024 | 1,635 | $10,023 | 67,228 (-2.4%) | Sale | ||
|
Chief Financial Officer
|
Dec 2, 2024 | 1,042 | $10,000 | 128,423 (+0.8%) | Grant | |
| Dec 2, 2024 | 6,409 | $39,351 | 52,214 (-12.3%) | Sale | ||
| Dec 2, 2024 | 2,431 | $10,000 | 68,863 (+3.5%) | Grant | ||
| Dec 2, 2024 | 10,000 | $26,900 | 58,623 (+17.1%) | Exercise/Conversion | ||
|
Chief Financial Officer
|
Nov 18, 2024 | 15,816 | $38,749 | 127,381 (+12.4%) | Exercise/Conversion | |
| Nov 4, 2024 | 2,431 | $10,478 | 66,432 (-3.7%) | Sale | ||
|
Chief Financial Officer
|
Oct 31, 2024 | 1,042 | $10,000 | 111,565 (+0.9%) | Grant | |
| Oct 31, 2024 | 2,431 | $10,000 | 68,863 (+3.5%) | Grant | ||
| Oct 8, 2024 | 1,406 | $6,369 | 48,623 (-2.9%) | Sale | ||
| Oct 8, 2024 | 1,960 | $4,998 | 50,029 (+3.9%) | Exercise/Conversion | ||
| Oct 1, 2024 | 2,431 | $12,009 | 66,432 (-3.7%) | Sale | ||
| Sep 30, 2024 | 2,431 | $10,000 | 68,863 (+3.5%) | Grant | ||
|
Chief Financial Officer
|
Sep 30, 2024 | 1,042 | $10,000 | 110,523 (+0.9%) | Grant | |
| Sep 4, 2024 | 2,431 | $13,419 | 66,432 (-3.7%) | Sale | ||
| Aug 31, 2024 | 2,431 | $10,000 | 68,863 (+3.5%) | Grant | ||
|
Chief Financial Officer
|
Aug 31, 2024 | 1,042 | $10,000 | 109,481 (+1.0%) | Grant | |
|
Chief Executive Officer
|
Aug 1, 2024 | 2,431 | $15,206 | 187,471 (-1.3%) | Sale | |
|
Chief Financial Officer
|
Jul 31, 2024 | 1,042 | $10,000 | 108,439 (+1.0%) | Grant | |
|
Chief Executive Officer
|
Jul 31, 2024 | 2,431 | $10,000 | 189,902 (+1.3%) | Grant | |
| Jul 5, 2024 | 1,173 | $7,073 | 46,457 (-2.5%) | Sale | ||
| Jul 5, 2024 | 1,792 | $5,000 | 47,630 (+3.8%) | Exercise/Conversion | ||
|
Chief Executive Officer
|
Jul 2, 2024 | 2,431 | $14,902 | 187,471 (-1.3%) | Sale | |
|
Chief Executive Officer
|
Jul 1, 2024 | 2,431 | $10,000 | 189,902 (+1.3%) | Grant | |
|
Chief Financial Officer
|
Jul 1, 2024 | 1,042 | $10,000 | 107,397 (+1.0%) | Grant |